Cannabis investors see the 2024 U.S. election as critical for cannabis policy, especially regarding federal rescheduling. This change would recognize cannabis’ medical uses, leading to more research, better banking access, and lower tax burdens for businesses.
Trump has recently expressed support for rescheduling cannabis to Schedule III, which would alleviate financial burdens for the industry. He emphasizes the importance of state autonomy and banking reform, both of which could help the cannabis sector overcome challenges associated with its current Schedule I status. The only uncertainty is how significantly the Trump administration could influence the pace of cannabis reform.
With upcoming regulatory changes, the cannabis industry is set for significant growth. Investors may find unique opportunities in stocks linked to potential federal reform, such as Novus Cannabis MedPlan ($NDEV), which aims to make medical cannabis more affordable and accessible through insurance-backed health plans.
